Retraction: Fructose mediated non-alcoholic fatty liver is attenuated by HO-1-SIRT1 module in murine hepatocytes and mice fed a high fructose diet (PLoS ONE (2015) 10:6 (e0128648) DOI: 10.1371/journal.pone.0128648);Fructose mediated non-alcoholic fatty liver is attenuated by HO-1-SIRT1 module in murine hepatocytes and mice fed a high fructose diet

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Sodhi, Komal ^a   Puri, Nitin ^b   Favero, Gaia ^c   Stevens, Sarah ^a   Meadows, Charles ^a   Abraham, Nader G ^d   Rezzani, Rita ^c   Ansinelli, Hayden ^a   Lebovics, Edward ^d   Shapiro, Joseph I ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIVERDIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID SYNTHASE; FRUCTOSE; GELATINASE A; HEME; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOPROSTANE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTOPORPHYRIN COBALT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SIRTUIN 1; SMALL INTERFERING RNA; SUPEROXIDE; TEMPOL; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; FAS ANTIGEN; FAS PROTEIN, MOUSE; HMOX1 PROTEIN, MOUSE; MEMBRANE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIRT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELEVATED BLOOD PRESSURE; GENE EXPRESSION; INSULIN RESISTANCE; LIPID STORAGE; LIPOGENESIS; LIVER CELL; LIVER FIBROSIS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; ANIMAL; BLOOD; BLOOD PRESSURE; C57BL MOUSE; CELL CULTURE; DIET; ENZYME ACTIVATION; GENETICS; LIVER; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE;

MURINAE; MUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIGENS, CD95; BLOOD PRESSURE; CELLS, CULTURED; DIET; ENZYME ACTIVATION; FRUCTOSE; HEME OXYGENASE-1; HEPATOCYTES; INSULIN RESISTANCE; LIVER; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PPAR ALPHA; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIRTUIN 1; TRIGLYCERIDES;

EID: 84939211429     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0259219     Document Type: Erratum

References (65)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274-285. doi:10.1111/j.1365-2036.2011.04724.x PMID: 21623852.
2. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 2011; 140:124-131. doi:10.1053/j.gastro.2010.09.038 PMID: 20858492.
3. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, et al. Prevalence of nonalcoholic fatty liver disease in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013; 178:38-45. doi:10.1093/aje/kws448 PMID: 23703888.
4. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13:3540-3553. PMID: 17659704.
5. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917-923. PMID: 12668987.
6. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22:1129- 1133. PMID: 16108837.
7. Delgado JS. Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med 2008; 19:75-82. doi:10.1016/j.ejim.2007.02.034 PMID: 18249301.
8. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16:1941-1951. PMID: 20370677.
9. Fon TK, Rozman D. Nonalcoholic Fatty liver disease: Focus on lipoprotein and lipid deregulation. J Lipids 2011; 2011:783976. doi:10.1155/2011/783976 PMID: 21773052.
10. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: An eleven-year follow-up study. Am J Gastroenterol 2009; 104:861-867. doi:10.1038/ajg.2009.67 PMID: 19293782.
11. Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013; 98:483-495. doi:10.1210/jc.2012-3093 PMID: 23293330.
12. Abel T, Feher J. [Non-alcoholic fatty liver disease and cardiovascular risk]. Orv Hetil 2008; 149:1299- 1305. doi:10.1556/OH.2008.28418 PMID: 18617457.
13. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5:1544-1560. doi:10.3390/nu5051544 PMID: 23666091.
14. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191:235-240. PMID: 16970951.
15. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013; 230:258-267. doi:10.1016/j.atherosclerosis.2013.07.052 PMID: 24075754.
16. Pettinelli P, Obregon AM, Videla LA. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease. Nutr Hosp 2011; 26:441-450. doi:10.1590/S0212-16112011000300003 PMID: 21892559.
17. Abdelmalek MF, Lazo M, Horska A, Bonekamp S, Lipkin EW, Balasubramanyam A, et al. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology 2012; 56:952-960. doi:10.1002/hep.25741 PMID: 22467259.
18. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51:1961-1971. doi:10.1002/hep.23535 PMID: 20301112.
19. Basaranoglu M, Basaranoglu G, Sabuncu T, Senturk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013; 19:1166-1172. doi:10.3748/wjg.v19.i8.1166 PMID: 23482247.
20. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010; 7:251-264. doi:10.1038/nrgastro.2010.41 PMID: 20368739.
21. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012; 23:203-208. doi:10.1016/j.jnutbio.2011.09.006 PMID: 22129639.
22. Basaranoglu M, Basaranoglu G, Sabuncu T, Senturk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013; 19:1166-1172. doi:10.3748/wjg.v19.i8.1166 PMID: 23482247.
23. Longato L. Non-alcoholic fatty liver disease (NAFLD): A tale of fat and sugar? Fibrogenesis Tissue Repair 2013; 6:14. doi:10.1186/1755-1536-6-14 PMID: 23866299.
24. Rebollo A, Roglans N, Alegret M, Laguna JC. Way back for fructose and liver metabolism: Bench side to molecular insights. World J Gastroenterol 2012; 18:6552-6559. doi:10.3748/wjg.v18.i45.6552 PMID: 23236229.
25. Johnson RJ, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, Feig DI, et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 2009; 30:96-116. doi:10.1210/er.2008-0033 PMID: 19151107.
26. Garcia-Galiano D, Sanchez-Garrido MA, Espejo I, Montero JL, Costan G, Marchal T, et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007; 17:493-503. PMID: 17608262.
27. Theret N, Lehti K, Musso O, Clement B. MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells. Hepatology 1999; 30:462-468. PMID: 10421655.
28. Kato J, Sato Y, Inui N, Nakano Y, Takimoto R, Takada K, et al. Ethanol induces transforming growth factor-alpha expression in hepatocytes, leading to stimulation of collagen synthesis by hepatic stellate cells. Alcohol Clin Exp Res 2003; 27:58S-63S. PMID: 12960509.
29. Puri N, Sodhi K, Haarstad M, Kim DH, Bohinc S, Foglio E, et al. Heme induced oxidative stress attenuates sirtuin1 and enhances adipogenesis in mesenchymal stem cells and mouse pre-adipocytes. J Cell Biochem 2012; 113:1926-1935. doi:10.1002/jcb.24061 PMID: 22234917.
30. Yamazaki Y, Usui I, Kanatani Y, Matsuya Y, Tsuneyama K, Fujisaka S, et al. Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am J Physiol Endocrinol Metab 2009; 297:E1179-E1186. doi:10.1152/ajpendo.90997.2008 PMID: 19724016.
31. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009; 9:327- 338. doi:10.1016/j.cmet.2009.02.006 PMID: 19356714.
32. Chung S, Yao H, Caito S, Hwang JW, Arunachalam G, Rahman I. Regulation of SIRT1 in cellular functions: Role of polyphenols. Arch Biochem Biophys 2010; 501:79-90. doi:10.1016/j.abb.2010.05.003 PMID: 20450879.
33. Berberat PO, Katori M, Kaczmarek E, Anselmo D, Lassman C, Ke B, et al. Heavy chain ferritin acts as an antiapoptotic gene that protects livers from ischemia reperfusion injury. FASEB J 2003; 17:1724- 1726. PMID: 12958189.
34. Li M, Kim DH, Tsenovoy PL, Peterson SJ, Rezzani R, Rodella LF, et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008; 57:1526-1535. doi:10.2337/db07-1764 PMID: 18375438.
35. Cao J, Peterson SJ, Sodhi K, Vanella L, Barbagallo I, Rodella LF, et al. Heme oxygenase gene targeting to adipocytes attenuates adiposity and vascular dysfunction in mice fed a high-fat diet. Hypertension 2012; 60:467-475. doi:10.1161/HYPERTENSIONAHA.112.193805 PMID: 22753217.
36. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60:79-127. doi:10.1124/pr.107.07104PMID: 18323402.
37. Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A 2010; 107:12553- 12558. doi: 10.1073/pnas.1006962107 PMID: 20616029.
38. Stienstra R, Mandard S, Patsouris D, Maass C, Kersten S, Muller M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology 2007; 148:2753- 2763. PMID: 17347305.
39. Hinds TD Jr, Sodhi K, Meadows C, Fedorova L, Puri N, Kim DH, et al. Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. Obesity (Silver Spring) 2013.
40. Abraham NG, Camadro JM, Hoffstein ST, Levere RD. Effects of iron deficiency and chronic iron overloading on mitochondrial heme biosynthetic enzymes in rat liver. Biochim Biophys Acta 1986; 870:339- 349. PMID: 3955059.
41. daSilva JL, Tiefenthaler M, Park E, Escalante B, Schwartzman ML, Levere RD, et al. Tin-mediated heme oxygenase gene activation and cytochrome P450 arachidonate hydroxylase inhibition in spontaneously hypertensive rats. Am J Med Sci 1994; 307:173-181. PMID: 8160707.
42. Botros FT, Schwartzman ML, Stier CT Jr, Goodman AI, Abraham NG. Increase in heme oxygenase-1 levels ameliorates renovascular hypertension. Kidney Int 2005; 68:2745-2755. PMID: 16316349.
43. Sodhi K, Puri N, Inoue K, Falck JR, Schwartzman ML, Abraham NG. EET agonist prevents adiposity and vascular dysfunction in rats fed a high fat diet via a decrease in Bach 1 and an increase in HO-1 levels. Prost Other Lipid Mediat 2012; 98:133-142.
44. Estall JL, Ruas JL, Choi CS, Laznik D, Badman M, Maratos-Flier E, et al. PGC-1alpha negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erb(alpha) axis. Proc Natl Acad Sci U S A 2009; 106:22510-22515. doi: 10.1073/pnas.0912533106 PMID: 20018698.
45. Krahenbuhl L, Lang C, Ludes S, Seiler C, Schafer M, Zimmermann A, et al. Reduced hepatic glycogen stores in patients with liver cirrhosis. Liver Int 2003; 23:101-109. PMID: 12654132.
46. Burgess A, Li M, Vanella L, Kim DH, Rezzani R, Rodella L, et al. Adipocyte heme oxygenase-1 induction attenuates metabolic syndrome in both male and female obese mice. Hypertension 2010; 56:1124-1130. doi: 10.1161/HYPERTENSIONAHA.110.151423 PMID: 21041703.
47. Nicolai A, Li M, Kim DH, Peterson SJ, Vanella L, Positano V, et al. Heme Oxygenase-1 Induction Remodels Adipose Tissue and Improves Insulin Sensitivity in Obesity-Induced Diabetic Rats. Hypertension 2009; 53:508-515. doi: 10.1161/HYPERTENSIONAHA.108.124701 PMID: 19171794.
48. Kim DH, Burgess AP, Li M, Tsenovoy PL, Addabbo F, McClung JA, et al. Heme oxygenase-mediated increases in adiponectin decrease fat content and inflammatory cytokines, tumor necrosis factor-alpha and interleukin-6 in Zucker rats and reduce adipogenesis in human mesenchymal stem cells. J Pharmacol Exp Ther 2008; 325:833-840. doi: 10.1124/jpet.107.135285 PMID: 18334666.
49. Yang H, Zhao LF, Zhao ZF, Wang Y, Zhao JJ, Zhang L. Heme oxygenase-1 prevents liver fibrosis in rats by regulating the expression of PPARgamma and NF-kappaB. World J Gastroenterol 2012; 18:1680-1688. doi: 10.3748/wjg.v18.i14.1680 PMID: 22529699.
50. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 2002; 76:911-922. PMID: 12399260.
51. Abraham N, Tsenovoy P, McClung J, Drummond G. Heme oxygenase: A target gene for anti-diabetic and obsesity. Curr Pharm Des 2008; 14:412-421. PMID: 18289068.
52. Higdon AN, Benavides GA, Chacko BK, Ouyang X, Johnson MS, Landar A, et al. Hemin causes mitochondrial dysfunction in endothelial cells through promoting lipid peroxidation: The protective role of autophagy. Am J Physiol Heart Circ Physiol 2012; 302:H1394-H1409. doi: 10.1152/ajpheart.00584. 2011 PMID: 22245770.
53. Armutcu F, Coskun O, Gurel A, Kanter M, Can M, Ucar F, et al. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin Biochem 2005; 38:540-547. PMID: 15885234.
54. Kim E, Choi Y, Jang J, Park T. Carvacrol Protects against Hepatic Steatosis in Mice Fed a High-Fat Diet by Enhancing SIRT1-AMPK Signaling. Evid Based Complement Alternat Med 2013; 2013:290104.
55. Abraham NG, Sodhi K, Silvis AM, Vanella L, Favero G, Rezzani R, et al. CYP2J2 Targeting to Endothelial Cells Attenuates Adiposity and Vascular Dysfunction in Mice Fed a High-Fat Diet by Reprogramming Adipocyte Phenotype. Hypertension 2014.
56. Khitan Z, Harsh M, Sodhi K, Shapiro JI, Abraham NG. HO-1 Upregulation Attenuates Adipocyte Dysfunction, Obesity, and Isoprostane Levels in Mice Fed High Fructose Diets. J Nutr Metab 2014; 2014:980547. doi: 10.1155/2014/980547 PMID: 25295182.
57. Cao J, Sodhi K, Inoue K, Quilley J, Rezzani R, Rodella L, et al. Lentiviral-human heme oxygenase targeting endothelium improved vascular function in angiotensin II animal model of hypertension. Hum Gene Ther 2011; 22:271-282. doi: 10.1089/hum.2010.059 PMID: 20836698.
58. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 Suppl 1:S17-S29. PMID: 16540762.
59. Jiang JX, Chen X, Fukada H, Serizawa N, Devaraj S, Torok NJ. Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-alpha-converting enzyme activity in mice. Hepatology 2013; 58:1339-1348. doi: 10.1002/hep.26491 PMID: 23703665.
60. Vasko R, Xavier S, Chen J, Lin CH, Ratliff B, Rabadi M, et al. Endothelial Sirtuin 1 Deficiency Perpetrates Nephrosclerosis through Downregulation of Matrix Metalloproteinase-14: Relevance to Fibrosis of Vascular Senescence. J Am Soc Nephrol 2013.
61. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: The plot thickens. Diabet Med 2007; 24:1-6.
62. Xirouchakis E, Sigalas A, Manousou P, Calvaruso V, Pleguezuelo M, Corbani A, et al. Models for nonalcoholic fatty liver disease: A link with vascular risk. Curr Pharm Des 2008; 14:378-384. PMID: 18289064.
63. Cao J, Sodhi K, Puri N, Monu SR, Rezzani R, Abraham NG. High fat diet enhances cardiac abnormalities in SHR rats: Protective role of heme oxygenase-adiponectin axis. Diabetol Metab Syndr 2011; 3:37. doi: 10.1186/1758-5996-3-37 PMID: 22196253.
64. Li Q, Guo Y, Ou Q, Cui C, Wu WJ, Tan W, et al. Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway. Circulation 2009; 120:1222-1230. doi: 10.1161/CIRCULATIONAHA.108.778688 PMID: 19752329.
65. Peterson SJ, Kim DH, Li M, Positano V, Vanella L, Rodella LF, et al. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res 2009; 50:1293-1304. doi: 10.1194/jlr.M800610-JLR200 PMID: 19224872.